Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Bernard G CombeYoshiya TanakaMaya H BuchPeter NashGerd R BurmesterAlan J KivitzBeatrix BartokAlena PechonkinaKatrina XiaKahaku EmotoShungo KanoThijs K HendrikxRobert B M LandewéDaniel AletahaPublished in: Rheumatology and therapy (2022)
In high-risk (four PPFs) patients with MTX-IR RA, FIL200 and FIL100 showed similar reductions in disease activity versus placebo at W12 as in patients with fewer than four PPFs. mTSS in patients receiving FIL200 changed little from W24 to W52, while that in patients receiving FIL100 progressed comparably to patients who received adalimumab. Tolerability was comparable across treatment arms and subgroups.
Keyphrases
- disease activity
- poor prognosis
- rheumatoid arthritis
- systemic lupus erythematosus
- juvenile idiopathic arthritis
- long non coding rna
- rheumatoid arthritis patients
- ankylosing spondylitis
- double blind
- open label
- placebo controlled
- phase iii
- ulcerative colitis
- systemic sclerosis
- idiopathic pulmonary fibrosis
- study protocol